Navigation Links
Palatin Technologies' Listing Compliance Plan Accepted by NYSE Alternext US
Date:3/5/2009

CRANBURY, N.J., March 5 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Alternext US: PTN) reported that its exchange listing compliance plan submitted on January 23, 2009 has been accepted by the NYSE Alternext US LLC (the "Exchange," formerly known as the American Stock Exchange).

As reported on December 30, 2008, Palatin received notice from the Exchange that it was not in compliance with certain continued listing requirements under Sections 1003(a)(ii) and (iii) of the Exchange's Company Guide related to historical operating losses and shareholders' equity levels. This notice is described in more detail in Palatin's report on Form 8-K which was filed on December 30, 2008.

On February 27, 2009, the Exchange notified Palatin that it had accepted Palatin's plan for regaining compliance with the continued listing requirements of Sections 1003(a)(ii) and (iii), and that Palatin's listing on the Exchange was being continued pursuant to an extension.

Palatin may be able to continue its listing on the Exchange during the plan period through June 23, 2010, subject to periodic review by the Exchange to determine if Palatin is making progress consistent with the plan. Failure to make progress consistent with the plan or to regain compliance with the continued listing standards by June 23, 2010 could result in Palatin's shares being delisted from the Exchange. If Palatin's common stock was ultimately delisted from the Exchange, it would be expected to trade on the over-the-counter market, such as the OTC Bulletin Board securities market, a regulated quotation service that provides quotes, sale prices and volume information in over-the-counter equity securities.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company focused on discovering and developing targeted, receptor-specific small molecule and peptide therapeutics. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.

Forward-looking Statements

Statements about future expectations of Palatin Technologies, Inc., including statements about performance related to the plan for regaining compliance with Exchange continued listing requirements, its development programs, proposed indications for its product candidates, pre-clinical activities, marketing collaborations, and all other statements in this document other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Palatin's actual results may differ materially from those discussed in the forward-looking statements for various reasons, including, but not limited to Palatin's ability to fund development of its technology, ability to establish and successfully complete clinical trials and pre-clinical studies and the results of those trials and studies, dependence on its partners for certain development activities, need for regulatory approvals and commercial acceptance of its products, ability to protect its intellectual property, and other factors discussed in the Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
2. Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
3. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
4. Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
5. Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
6. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
7. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
8. Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
9. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
10. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
11. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... PUNE, India , April 28, 2016 ... PT, JT, Stirling, and Brayton Cryocoolers), Service (Technical Support, ... Application, and Geography - Global Forecast to 2022", published ... to USD 2.94 Billion by 2022, at a CAGR ... Browse 70 market data Tables and 94 Figures spread ...
(Date:4/28/2016)... NY (PRWEB) , ... April 28, 2016 , ... ... has made significant investments in recruiting top industry experts, and expanding its LATAM ... which provides industry-leading tools for clients to manage their clinical trial projects. , ...
(Date:4/27/2016)... ... ... The Pittcon Organizing Committee is pleased to announce that Charles “Chuck” Gardner was named ... 1987. Since then, he has served in a number of key leadership positions including ... program and exposition committees. In his professional career, Dr. Gardner is the director of ...
(Date:4/27/2016)... ... April 27, 2016 , ... The Board of Directors ... of John Tilton as Chief Commercial Officer.  Mr. Tilton joined Biohaven from Alexion ... commercial leaders responsible for the commercialization of multiple orphan drug indications. Mr. ...
Breaking Biology Technology:
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/23/2016)... 2016 Einzigartige ... und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler Kommunikationsdienste, ... SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie einzusetzen. ... Möglichkeit angeboten, im Rahmen mobiler Apps neben ...
Breaking Biology News(10 mins):